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Abstract
Background: Resectable lung adenocarcinoma is dominated by peripheral distribution, and surgical resection is the main
treatment protocol. However, high recurrence rate remains after surgery. Lung adenocarcinoma with epidermal growth
factor receptor (EGFR) mutation has strong invasion ability, but the effects of this mutation on local invasion in early lung
adenocarcinoma have been rarely studied. This study aimed to assess the effects of EGFR mutation on local invasion in
resectable lung adenocarcinoma.
Methods: A retrospective analysis of 103 patients clinically diagnosed with peripheral lung adenocarcinoma was included.
They underwent preoperative bronchoscopy, which indicated grades 2 or 3 bronchial involvement (lumen of the lobe or
segment). The associations of EGFR mutation with pleural invasion, endobronchial metastasis, and lymph node metastasis
were analyzed according to pathologies of pleural invasion and lymph node metastasis, as well as EGFR gene mutation
detected by postoperative pathological specimens. Statistical analyses were performed by unpaired Chi-square test using
the SPSS16.0 software.
Results: In patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates
were 62.5, 39.1, and 34.4%, respectively, indicating statistically significant differences (p = 0.003). Meanwhile, the pleural
invasion rate in patients with wild-type EGFR was 43.6%, significantly reduced compared with patients with mutated
EGFR (62.5%; p = 0.018). In addition, the endobronchial metastasis rate in patients with wild-type EGFR was 17.9%,
significantly lower than in patients with EGFR mutation (39.1%; p = 0.005). However, lymph node metastasis rates were
similar between EGFR mutated and wild-type patients (34.4 vs 25.6%, respectively, p > 0.05).
Conclusions: Early resectable lung adenocarcinoma patients with EGFR mutation showed a higher rate of local
invasion compared with those harboring wild-type EGFR. This finding provides a basis for improved therapy.
Trial registration: This study was supported by Project of Medical and Health Science Technology in Shandong
Province (2015WS0376)
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Background
Computed tomography (CT) diagnosis rate for early
peripheral lung adenocarcinoma is increasingly higher,
and surgical resection of lung segment and lobe is more
popular. However, high recurrence rate remains after
surgery. Selection of the surgical margin is one of the key
factors affecting recurrence. The EGFR gene affects the
invasion capability of lung adenocarcinoma. However,
how EGFR mutation helps early lung adenocarcinoma
invade local structures that has been rarely studied, and it
is not known whether it can provide a basis for treatment
in early lung adenocarcinoma. In this study, bronchial
nvasion was accurately assessed by preoperative bronchos-
copy, combined with postoperative pathologies of pleural
and lymph node metastases as well as EGFR gene muta-
tion assays, to further elucidate local invasion in early* Correspondence: ghongsheng@126.com
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resectable lung adenocarcinoma. Our data provide a
strong basis for improved therapy.
Methods
Patients
A retrospective analysis of 103 outpatients or inpatients
treated at Linyi People’s Hospital, between January 2011
and August 2015, were selected. They presented with
sputum, cough, chest pain, fever or blood sputum, and
were pathologically diagnosed with lung adenocarcinoma
postoperatively. They included 50 men (59.38 ±
10.038 years old), and 53 women (57.73 ± 11.706 years
old). Among them, there were 30 smokers, including 25
men and 5 women. The patients underwent high-
resolution CT (HRCT) examinations, and lesions were
found in the peripheral lung. Patients were tolerable to
bronchoscopy and surgery.
Examination methods
1) All patients underwent 64-sliced CT (Light Speed
VCT 64, GE Company Fairfield USA) plain and
enhanced scans, with layer thickness and interval
of 0.625 mm. The CT scanning ranged from the
superior aperture of thorax to the costophrenic
angle. Plain scans were first performed, followed
by bolus injection of contrast agent with a high-
pressure syringe (iopromide 300, 300 mgI/ml; flow
rate, 3 ml/s; total amount, 80 ml; cubital vein
injection). Enhanced scans were conducted in
delayed stage (30 s after venous stage). Three-
dimensional reconstruction was performed if
necessary; the horizontal plan was considered the
routine layer. Peripheral or central lung cancer
was initially determined. All patients underwent
bronchoscopic examination (BF260, Olympus,
Tokyo, Japan) and grades 2 or 3 (lumen of the
lobe or segment) bronchial invasions were found.
The surgical specimens were routinely fixed with
neutral formalin, paraffin-embedded, and H&E
stained for routine pathological examination.
Postoperative lung cancer was classified according
to the seventh edition of the TNM classification
of lung cancer in 2009 [1]. All preoperative
patients were confirmed no metastasis by
PET-CT, or cerebral MRI, bone ECT, and
abdomen ultrasound.
2) EGFR gene detection:
Postoperative pathological sections were used to
assess 18, 19, 20, and 21 exon mutation on ARMS-
PCR (scorpion amplification refractory mutation sys-
tem) [2] with Gene mutation detection kit pur-
chased from Amoy Diagnostics Co. Ltd. (Xiamen,
China).
Evaluation criteria
According to the pathological results, pleural invasion
was defined to extend beyond the elastic pleural layer,
and lymph node metastasis was diagnosed by postopera-
tive lymph node pathology. Endobronchial metastasis
referred to lumen of the lobe or segment (2 or 3 grade
bronchus) invaded by peripheral lung adenocarcinoma,
or other bronchial lumens were invaded beyond the lobe
containing the tumor. Features of metastasis bronchus:
mucosal hyperemia and edema, infiltration change,
polypoid change, etc.; meanwhile, lung adenocarcinoma
was confirmed by endoscopic biopsy and pathology. All
patients underwent a bronchoscopic examination, per-
formed by expert pulmonologists using an Olympus
EVIS bronchovideoscope BF260 (Olympus, Tokyo,
Japan). If no significant endobronchial lesions were
found in the most distal bronchi by bronchoscopy, the
patient was considered to have no endobronchial metas-
tasis. However, if a tumor mass or infiltration was visible
by bronchoscopy, the patient was considered to have
endobronchial metastasis. Bronchial grading was defined
as follows: tracheal, 0; right and left main bronchus, 1;
lobar bronchus, 2; segmental bronchus, 3.
Surgical procedure
In the VATS procedure, all patients underwent general
anesthesia with double lumen endotracheal intubation
and single lung ventilation. The patient was placed in
the lateral decubitus position. Thoracoscopic lobectomy
was performed through three or four incisions. We
placed a thoracoscope in the 7th or 8th intercostal space
in the middle or anterior axillary line. The main operat-
ing port of incision was located at the anterior axillary
line in the 4th or 5th intercostal space, with a length of
about 3 cm; the port just facing the lung hilus was the
best. A 1.5 cm auxiliary operating port was placed in the
auscultation triangle. The lung and pleural space were
carefully inspected for unexpected metastatic disease.
According to the various fissure situations, the manage-
ment sequence of pulmonary arteries, veins, and
bronchia was different. Pulmonary artery, vein, bron-
chus, and fissure were divided using an Endoscopic Lin-
ear Cutter. The pulmonary artery with smaller diameter
(<7 cm) was ligated using Hem-o-lok. Lymph node dis-
section was performed by standard procedure, removing
all accessible Hilar and mediastinal lymph nodes, includ-
ing levels L2–L4, and L7–L11 on the right side, and
levels L4–L11on the left side, according to the American
Thoracic Society classification.
For thoracotomy, a posterolateral skin incision ran-
ging in length from 20 to 25 cm was made. The la-
tissimus dorsi and serratus anterior muscles were
dissected along the fifth intercostal space. Thoracot-
omy was performed at the fifth intercostal space, with
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the fifth rib sectioned at the costovertebral angle. A
standard rib retractor was inserted. All resections were
performed in a conventional manner. Hilar and medi-
astinal lymph node dissection was performed in all pa-
tients, and the extent of mediastinal lymph node
dissection was the same as in the VATS group. One
chest tube was placed at the posterior aspect of the
chest cavity.
Statistical analysis
Statistical analyses were performed by unpaired Chi-
square test using the SPSS16.0 software. p < 0.05 was
considered statistically significant.
Results
According to postoperative pathological TNM staging, there
were 52, 24, and 27 stages I, II, and IIIA cases, respectively.
Patients with EGFR mutation represented 62.14% (64/103);
37.86% (39/103) harbored wild-type exon.
Local invasion
A total of 60 cases with pleural invasion were found,
including 43 and 17 patients with mutated and wild-
type EGFR, respectively; there were 32 cases of
lymph node metastasis, including 22 and 10 patients
with mutated and wild-type EGFR, respectively. A
total of 32 cases of endobronchial metastasis were
found, including 25 with mutated EGFR and 7 with
wild-type gene.
Among the 64 patients with EGFR mutation, pleural
invasion, endobronchial metastasis, and lymph node
metastasis rates were 62.5% (43/64), 39.1% (25/64), and
34.4% (22/64), respectively, showing statistically sig-
nificant differences (p = 0.003). For the 39 wild-type
patients, pleural invasion, endobronchial metastasis, and
lymph node metastasis rates were 43.6% (17/39), 17.9%
(7/39), and 25.6% (10/39), respectively, indicating sta-
tistically significant differences among the three groups
(p = 0.038). Interestingly, pleural invasion (p = 0.018) and
endobronchial metastasis (p = 0.005) rates in patients
with EGFR mutation were significantly higher compared
with those obtained for individuals harboring wild-type
EGFR. However, the difference in lymph node metastasis
rates between both groups was not statistically signifi-
cant (p > 0.05) (Tables 1 and 2) (Fig. 1).
Relationship between EGFR gene mutation and
pathological staging
p-stage I incidence was highest (54.7%, 35/64) in
patients with EGFR mutations, followed by p-stage IIIA
(28.1%,18/64), and p-stage II (17.2%, 11/64), indicating
statistically significant differences among the three stages
(p < 0.001). For patients without EGFR mutation, p-stage
I, p-stage II, and p-stage IIIA incidence rates were 43.6,
33.3, and 23.1%, respectively, and the differences were
not statistically significant (p = 0.158) (Table 3).
Surgical methods
Three patients underwent sleeved lobectomy, including
2 and 1 with mutated and wild-type EGFR, respectively;
8 patients had pulmonary wedge resection, including 4
in each group; 3 patients underwent segmentectomy,
including 1 and 2 with mutated and wild-type EGFR, re-
spectively; 85 patients underwent lobectomy, including
31 harboring wild-type EGFR and 54 with mutated gene;
4 patients underwent two lobe combination resection,
including 3 and 1 with mutated and wild-type EGFR. 4
patients (3 patients with pulmonary wedge resection and
1 patient with two lobe combination resections) had
positive margin resection, including 1 with wild-type
gene and 3 harboring mutated EGFR (Table 4).
Discussion
With recent advances in diagnostic techniques for
lung cancer, detection rate is increasingly higher, and
more and more resectable lung adenocarcinomas are
found in early stage. In this study, postoperative patients
with p-stage I and EGFR mutation accounted for 54.7%
(p = 0.000), followed by p-stage IIIA (28.1%, 18/64), and p-
stage II (17.2%, 11/64). In addition, wedge resection, pul-
monary segmentectomy and lobectomy were increasingly
used, while invasion of peripheral structure by early
Table 1 Relationship between local invasion and gene mutation status
Metastasis Mutated N = 64 Wild-type
N = 39
P value (mutated
vs. wild-type)Exon 18 N = 2 exon 19 N = 36 exon 21 N = 26
Pleural invasion 1 22 20 17 p = 0.018
Lymph node metastasis 0 12 10 10 p > 0.05
Endobronchial metastasis 1 16 8 7 p = 0.005
Table 2 Amounts of grades 2 or 3 bronchus invasion
Diameter Total Endobronchial metastasis
(grades 2 or 3 bronchus)
No endobronchial metastasis
(grades 2 or 3 bronchus)
<2 cm 31 5 26
2.1–3 cm 28 7 21
3.1–5 cm 26 10 16
5.1–7 cm 10 7 3
>7.1 cm 8 3 5
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lung adenocarcinoma affects postoperative recurrence
or treatment [3].
Common local metastases of peripheral lung adeno-
carcinoma include pleural, endobronchial and lymphatic
metastases. Chest CT can be used to assess lymph node
enlargement and tumor diameter, but is not sensitive
enough to differentiate bronchial mucous membrane
and visceral pleural invasion. Postoperative specimens
are used to determine pleural and lymph node invasions,
but cannot help identify endobronchial metastasis. Since
early lung adenocarcinoma can expand along the bron-
chus [4], bronchoscopy can accurately assess endobron-
chial metastasis; however, the traditional endoscopic
examination aims mainly to obtain pathological diagno-
sis and does not guide in selecting a surgical procedure
for peripheral lung adenocarcinoma in the aspect of
endobronchial metastasis [5]. In this study, endobron-
chial metastasis was defined as grades 2 or 3 invasions
in central bronchial anatomic regions in patients with
lung adenocarcinoma. Since lobectomy is more difficult
in cases with tumor invading lobar bronchus opening or
adjacent principal bronchus [6], the sleeved protocol is
superior in increasing the length of bronchial incision
[7]. When metastatic tumors are observable by bron-
choscopy, there may be a high possibility of positive
stump after simple lobectomy [8–10]. The recurrence
rate after wedge resection is higher than that after pul-
monary segmentectomy, while the local recurrence after
segmentectomy is more common than when lobectomy
is performed [11–15]. Endobronchial metastasis is sig-
nificantly increased in patients with EGFR mutation, in
agreement with our data presented above 39.1 vs 17.9%
in patients with mutation and wild-type EGFR, respect-
ively; (p = 0.005). Patients mutated for EGFR might
present higher recurrence and decreased 5-year survival
rates [16], with better efficacy to chemoradiotherapy
after surgery than other types of metastasis [17].
Pleural invasion rate was highest in peripheral lung
adenocarcinoma, with patients harboring EGFR muta-
tion showing significantly higher values (62.5%) com-
pared with those without EGFR mutation (p = 0.018).
Moreover, recurrence rate after wedge resection was
shown to be high in lung adenocarcinoma patients
with stage I and pleural invasion [15, 18]. This study
Fig. 1 CT features and endobronchial metastasis. Endobronchial metastasis in peripheral lung adenocarcinoma. CT scan showing lung cancer in
the medial anterior basal segment of left lower lobe, with pleural retraction. Appearance obtained by bronchoscopy. Left lung lower lobe and
upper lobe bronchial mucosal hyperemia, infiltration change, and luminal stenosis. Endoscopic biopsy pathology, adenocarcinoma; EGFR
mutation, exon 19 deletion mutation
Table 3 Effects of EGFR mutation on pathological staging
p-stage I p-stage II p-stage IIIA
Mutated 35 11 18
Wild-type 17 13 9
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confirmed a stronger local invasion in patients with EGFR
gene mutation, with significantly higher pleural and endo-
bronchial metastases compared with patients without mu-
tation. Furthermore, pleural and endobronchial metastases
were significantly more common than lymph node metas-
tasis. Invasion of local structure in early lung adenocarcin-
oma was to a certain extent associated with postoperative
recurrence, which can help provide a basis for surgical
treatment. Since p-stage I lung adenocarcinoma incidence
is significantly increased in patients with EGFR mutation, it
is critical to select an appropriate surgical procedure,
especially that with significant effects on the incision
margin and recurrence.
Sole TNM staging is unable to predict early lung
adenocarcinoma invasion, unlikely to identify recurrence
in patients after surgical resection [19, 20], and unable
to predict chemotherapeutic efficacy. The relationship
between EGFR mutation and peripheral structure inva-
sion can provide a basis for comprehensive therapy. In-
deed, postoperative patients with EGFR mutation show
higher efficacy rates to targeted therapy and chemother-
apy compared with wild-type patients [21]. Patients
harboring EGFR mutation are prone to recurrence in
the incision margin [22–24], and have a high metastasis
rate [25]; however, they still show higher survival after
recurrence [26–28]. For instance, the 5-year survival rate
in patients with EGFR mutation was shown to be higher
than that of cases without mutation [21], which may be
related to drug sensitivity and comprehensive treatment.
Therefore, clarifying the clinical characteristics of early
lung adenocarcinoma patients with EGFR mutation aims
to provide a basis for clinical treatment.
The limitation of this study lies in that only patients
with operable lung adenocarcinoma were assessed, not
including other types of lung cancer. Therefore, fur-
ther multi-factor, large sample, and multi-center stud-
ies are needed to confirm the association of local
structure invasion in early lung adenocarcinoma with
EGFR.
Conclusions
Compared with early resectable lung adenocarcinoma
patients harboring wild-type EGFR, those with EGFR
mutation showed a higher rate of local invasion, with
pleural invasion most common. In addition, endobron-
chial metastasis incidence was higher than that of lymph
node metastasis, suggesting the influence of EGFR muta-
tion on resection scope.
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